These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Dendritic cells from bench to bedside and back. Adema GJ Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337 [TBL] [Abstract][Full Text] [Related]
26. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro. Keijzer C; Spiering R; Silva AL; van Eden W; Jiskoot W; Vervelde L; Broere F J Control Release; 2013 May; 168(1):35-40. PubMed ID: 23500056 [TBL] [Abstract][Full Text] [Related]
27. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790 [TBL] [Abstract][Full Text] [Related]
28. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. Pavot V; Rochereau N; Primard C; Genin C; Perouzel E; Lioux T; Paul S; Verrier B J Control Release; 2013 Apr; 167(1):60-7. PubMed ID: 23352911 [TBL] [Abstract][Full Text] [Related]
29. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. Han R; Zhu J; Yang X; Xu H J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162 [TBL] [Abstract][Full Text] [Related]
30. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation. Thomann-Harwood LJ; Kaeuper P; Rossi N; Milona P; Herrmann B; McCullough KC J Control Release; 2013 Mar; 166(2):95-105. PubMed ID: 23220107 [TBL] [Abstract][Full Text] [Related]
31. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. Uto T; Akagi T; Toyama M; Nishi Y; Shima F; Akashi M; Baba M Immunol Lett; 2011 Oct; 140(1-2):36-43. PubMed ID: 21693134 [TBL] [Abstract][Full Text] [Related]
33. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer. Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429 [TBL] [Abstract][Full Text] [Related]
34. Part I: targeted particles for cancer immunotherapy. Hamdy S; Haddadi A; Ghotbi Z; Hung RW; Lavasanifar A Curr Drug Deliv; 2011 May; 8(3):261-73. PubMed ID: 21453265 [TBL] [Abstract][Full Text] [Related]
35. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445 [TBL] [Abstract][Full Text] [Related]
36. Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans. Oosterhoff D; Heusinkveld M; Lougheed SM; Kosten I; Lindstedt M; Bruijns SC; van Es T; van Kooyk Y; van der Burg SH; de Gruijl TD J Immunol; 2013 Apr; 190(7):3338-45. PubMed ID: 23467931 [TBL] [Abstract][Full Text] [Related]
37. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Cruz LJ; Rueda F; Cordobilla B; Simón L; Hosta L; Albericio F; Domingo JC Mol Pharm; 2011 Feb; 8(1):104-16. PubMed ID: 21121669 [TBL] [Abstract][Full Text] [Related]
39. An overview of adjuvant formulations and delivery systems. García A; De Sanctis JB APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674 [TBL] [Abstract][Full Text] [Related]
40. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. Lim SN; Kuhn S; Hyde E; Ronchese F J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]